These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 15947877

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Insulin-like growth factors and prostate cancer: a population-based case-control study in China.
    Chokkalingam AP, Pollak M, Fillmore CM, Gao YT, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF, Hsing AW.
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):421-7. PubMed ID: 11352850
    [Abstract] [Full Text] [Related]

  • 3. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
    Miyata Y, Sakai H, Hayashi T, Kanetake H.
    Prostate; 2003 Feb 01; 54(2):125-32. PubMed ID: 12497585
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
    Khosravi J, Diamandi A, Mistry J, Scorilas A.
    J Clin Endocrinol Metab; 2001 Feb 01; 86(2):694-9. PubMed ID: 11158033
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
    Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D.
    Cancer Res; 2003 Jul 15; 63(14):3991-4. PubMed ID: 12873996
    [Abstract] [Full Text] [Related]

  • 8. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
    Platz EA, Leitzmann MF, Rifai N, Kantoff PW, Chen YC, Stampfer MJ, Willett WC, Giovannucci E.
    Cancer Epidemiol Biomarkers Prev; 2005 May 15; 14(5):1262-9. PubMed ID: 15894683
    [Abstract] [Full Text] [Related]

  • 9. High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort.
    Stattin P, Rinaldi S, Biessy C, Stenman UH, Hallmans G, Kaaks R.
    J Clin Oncol; 2004 Aug 01; 22(15):3104-12. PubMed ID: 15284261
    [Abstract] [Full Text] [Related]

  • 10. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.
    Janssen JA, Wildhagen MF, Ito K, Blijenberg BG, Van Schaik RH, Roobol MJ, Pols HA, Lamberts SW, Schröder FH.
    J Clin Endocrinol Metab; 2004 Sep 01; 89(9):4391-6. PubMed ID: 15356036
    [Abstract] [Full Text] [Related]

  • 11. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
    Aksoy Y, Aksoy H, Bakan E, Atmaca AF, Akçay F.
    Urol Int; 2004 Sep 01; 72(1):62-5. PubMed ID: 14730168
    [Abstract] [Full Text] [Related]

  • 12. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin.
    Chen C, Lewis SK, Voigt L, Fitzpatrick A, Plymate SR, Weiss NS.
    Cancer; 2005 Jan 01; 103(1):76-84. PubMed ID: 15540247
    [Abstract] [Full Text] [Related]

  • 13. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen.
    Finne P, Auvinen A, Koistinen H, Zhang WM, Määttänen L, Rannikko S, Tammela T, Seppälä M, Hakama M, Stenman UH.
    J Clin Endocrinol Metab; 2000 Aug 01; 85(8):2744-7. PubMed ID: 10946875
    [Abstract] [Full Text] [Related]

  • 14. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
    Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ.
    Urol Oncol; 2012 Aug 01; 30(4):408-14. PubMed ID: 20884247
    [Abstract] [Full Text] [Related]

  • 15. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
    Zhigang Z, Jieming L, Su L, Wenlu S.
    J Surg Oncol; 2007 Jul 01; 96(1):54-61. PubMed ID: 17345593
    [Abstract] [Full Text] [Related]

  • 16. Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays.
    Rinaldi S, Kaaks R, Zeleniuch-Jacquotte A, Arslan AA, Shore RE, Koenig KL, Dossus L, Riboli E, Stattin P, Lukanova A, Toniolo P.
    Cancer Epidemiol Biomarkers Prev; 2005 Jan 01; 14(1):48-52. PubMed ID: 15668475
    [Abstract] [Full Text] [Related]

  • 17. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer.
    Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD, Giles GG.
    Cancer Epidemiol Biomarkers Prev; 2007 Apr 01; 16(4):763-8. PubMed ID: 17416768
    [Abstract] [Full Text] [Related]

  • 18. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.
    Schernhammer ES, Holly JM, Pollak MN, Hankinson SE.
    Cancer Epidemiol Biomarkers Prev; 2005 Mar 01; 14(3):699-704. PubMed ID: 15767352
    [Abstract] [Full Text] [Related]

  • 19. Ratios of IGF-I, IGF binding protein-3, and prostate-specific antigen in prostate cancer detection.
    Stattin P, Stenman UH, Riboli E, Hallmans G, Kaaks R.
    J Clin Endocrinol Metab; 2001 Dec 01; 86(12):5745-8. PubMed ID: 11739433
    [Abstract] [Full Text] [Related]

  • 20. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.
    Stattin P, Bylund A, Rinaldi S, Biessy C, Déchaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R.
    J Natl Cancer Inst; 2000 Dec 06; 92(23):1910-7. PubMed ID: 11106682
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.